Cost-effectiveness of umeclidinium/vilanterol versus aclidinium monotherapy for symptomatic COPD in Colombia: a lifetime Markov model

BACKGROUND: To evaluate the lifetime cost-effectiveness of once-daily umeclidinium/vilanterol (UMEC/VI) versus twice-daily aclidinium monotherapy for symptomatic chronic obstructive pulmonary disease (COPD) in Colombia. RESEARCH DESIGN AND METHODS: A lifetime Markov model with monthly cycles simulated moderate-to-very-severe COPD in a cohort aged 65 years, incorporating age- and severity-specific background mortality and a 12% case-fatality probability after each severe exacerbation. Comparative efficacy came from a published network meta-analysis; comparator exacerbation probabilities were derived on the rate scale. Costs and quality-adjusted life-years (QALYs) were discounted at 5% annually. Deterministic, scenario, and probabilistic sensitivity analyses were performed. RESULTS: UMEC/VI yielded 8.108 QALYs at US$24,956 per patient versus 6.312 QALYs and US$29,994 for aclidinium (incremental 1.796 QALYs; US$5,038 saved), making UMEC/VI dominant (net monetary benefit US$14,341). UMEC/VI was dominant in 94.7% and cost-effective in 98.6% of probabilistic simulations. Without its exacerbation benefit, UMEC/VI was not cost-effective (net monetary benefit -US$859). CONCLUSIONS: UMEC/VI is a high-value COPD maintenance therapy in Colombia, driven by exacerbation reduction rather than drug pricing and conditional on persistence of its clinical benefit.

Authors

Institutions

Publication Details

Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Published
2026-11-19
DOI
https://doi.org/10.1080/14737167.2026.2767344
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cost-effectiveness of umeclidinium/vilanterol versus aclidinium monotherapy for symptomatic COPD in Colombia: a lifetime Markov model

Jefferson Antonio Buendía
3 links
Expert Review of Pharmacoeconomics & Outcomes Research
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Cost-effectiveness of umeclidinium/vilanterol versus aclidinium monotherapy for symptomatic COPD in Colombia: a lifetime Markov model

Jefferson Antonio Buendía
article en

Abstract

BACKGROUND: To evaluate the lifetime cost-effectiveness of once-daily umeclidinium/vilanterol (UMEC/VI) versus twice-daily aclidinium monotherapy for symptomatic chronic obstructive pulmonary disease (COPD) in Colombia. RESEARCH DESIGN AND METHODS: A lifetime Markov model with monthly cycles simulated moderate-to-very-severe COPD in a cohort aged 65 years, incorporating age- and severity-specific background mortality and a 12% case-fatality probability after each severe exacerbation. Comparative efficacy came from a published network meta-analysis; comparator exacerbation probabilities were derived on the rate scale. Costs and quality-adjusted life-years (QALYs) were discounted at 5% annually. Deterministic, scenario, and probabilistic sensitivity analyses were performed. RESULTS: UMEC/VI yielded 8.108 QALYs at US$24,956 per patient versus 6.312 QALYs and US$29,994 for aclidinium (incremental 1.796 QALYs; US$5,038 saved), making UMEC/VI dominant (net monetary benefit US$14,341). UMEC/VI was dominant in 94.7% and cost-effective in 98.6% of probabilistic simulations. Without its exacerbation benefit, UMEC/VI was not cost-effective (net monetary benefit -US$859). CONCLUSIONS: UMEC/VI is a high-value COPD maintenance therapy in Colombia, driven by exacerbation reduction rather than drug pricing and conditional on persistence of its clinical benefit.

Expert Review of Pharmacoeconomics & Outcomes Research
Universidad de Antioquia (CO)
Good health and well-being
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon